Dr Mengyu Lu > Kirkland & Ellis > Hong Kong, Hong Kong > Lawyer Profile
Kirkland & Ellis Offices
26TH FLOOR, GLOUCESTER TOWER
THE LANDMARK, 15 QUEEN'S ROAD CENTRAL
HONG KONG
Hong Kong
- Firm Profile
- Go to...
Dr Mengyu Lu
Work Department
Corporate
Position
Partner
Career
Dr. Mengyu Lu heads the Firm’s Asia capital markets practice. Dr. Lu has extensive experience in initial public offerings, SPACs, pre-IPO financings, mergers and acquisitions, and various follow-on offerings or compliance matters by listed companies. She is particularly well recognized in advising issuers in the “new economy” sectors, including healthcare, semiconductor, artificial intelligence, TMT and consumer sectors. In addition to corporate issuers, she also advises major investment banks, private equity and venture capital firms on capital markets and M&A matters. Her major corporate clients include, among others, Super Hi, ZG Group, NIO, Will Semiconductor and Kelun Biotech.
Dr. Lu was recognized as a leading lawyer for China equity capital markets by Chambers Global and Chambers Greater China, a “Leading Individual” for Hong Kong equity capital markets by Legal 500, and a “Highly Regarded” lawyer for Hong Kong capital markets by IFLR1000. IFLR named her to its list of 2021 “Asia Best Lawyers”, and Asian Legal Business named her to its 2021 Asia “40 under 40” list. She was also listed in China Business Law Journal’s “China’s Elite 100 Lawyers” in 2016-2018 and 2020-2021.
Languages
English, Mandarin, Cantonese
Education
Chinese Academy of Social Sciences, Ph.D., Economics
Duke University School of Law, LL.M.
China University of Political Science and Law, LL.B.
Lawyer Rankings
China > Corporate and M&A: foreign firms
Highly regarded for its expert handling of cross-border SPAC and de-SPAC transactions, in conjunction with a strong corporate finance offering, the Kirkland & Ellis International LLP team is renowned for its ‘responsiveness’ and ‘professionalism’. The firm regularly advises on major take-private transactions and sales of shares, with the duo of Joey Chau and Brian Ho spearheading the practice from Hong Kong. Mengyu Lu is knowledgeable on multi-jurisdictional M&A transactions, while Jesse Sheley and Peng Yu predominantly concentrate on the TMT and life sciences spaces. All lawyers mentioned are Hong Kong-based.
Hong Kong > Capital markets (equity)
(Leading partners)Kirkland & Ellis maintains a solid roster of New York and locally-qualified practitioners based in Hong Kong, who work closely with PRC-based lawyers to provide a ‘very strong’ service to both issuers and underwriters on Hong Kong listings and follow-on offerings, as well as US IPOs and Rule 144A and Regulation S offerings. Mengyu Lu heads the team from Hong Kong, following David Zhang’s departure in January 2024, and draws upon vast experience assisting Chinese companies go public on the HKSE, including under the relatively newly enacted Rule 18A aimed at helping pre-revenue biotech companies go public. Lu is also one of a number in the team, including Joey Chau and Brian Ho, who have real world expertise of handling mandates under the newly enacted Hong Kong SPAC regime, with all three recently being involved in the first announced de-SPAC transaction since the introduction of the new listing regime in 2022.
Lawyer Rankings
Top Tier Firm Rankings
- Capital markets (equity)
- Corporate (including M&A)
- Investment funds
- Private equity
- Restructuring and insolvency